Table 1.
Baseline characteristics of patients with chronic hypophosphatemia (n = 154).
| Variables | Case | Control | P-value* | ||||
|---|---|---|---|---|---|---|---|
| Total (n = 154) |
Men (n = 76) |
Women (n = 78) |
Total (n = 1540) |
Men (n = 760) |
Women (n = 780) |
||
| Age at baseline, years, mean (SD) | 31.5 (26.1) | 32.6 (25.6) | 30.4 (26.6) | 31.5 (26.0) | 32.6 (25.5) | 30.4 (26.4) | 1.00 |
| Age group, n (%) | 1.00 | ||||||
| 0 | 2 (1.3) | 1 (1.3) | 1 (1.3) | 20 (1.3) | 10 (1.3) | 10 (1.3) | |
| 1–4 | 33 (22.4) | 17 (22.4) | 16 (20.5) | 330 (21.4) | 170 (22.4) | 160 (20.5) | |
| 5–9 | 12 (7.8) | 4 (5.3) | 8 (10.3) | 120 (7.8) | 40 (5.3) | 80 (10.3) | |
| 10–14 | 11 (7.1) | 3 (4.0) | 8 (10.3) | 110 (7.1) | 30 (4.0) | 80 (10.3) | |
| 15–19 | 9 (5.8) | 4 (5.3) | 5 (6.4) | 90 (5.8) | 40 (5.3) | 50 (6.4) | |
| 20–29 | 13 (8.4) | 8 (10.5) | 5 (6.4) | 130 (8.4) | 80 (10.5) | 50 (6.4) | |
| 30–39 | 13 (8.4) | 4 (5.3) | 8 (10.3) | 130 (8.4) | 50 (6.6) | 80 (10.3) | |
| 40–49 | 16 (10.4) | 12 (15.8) | 4 (5.1) | 160 (10.4) | 120 (15.8) | 40 (5.1) | |
| 50–59 | 16 (10.4) | 8 (10.5) | 8 (10.3) | 160 (10.4) | 80 (10.5) | 80 (10.3) | |
| 60–69 | 16 (10.4) | 8 (10.5) | 8 (10.3) | 160 (10.4) | 80 (10.5) | 80 (10.3) | |
| 70–85 | 13 (8.4) | 6 (7.9) | 7 (9.0) | 130 (8.5) | 60 (7.9) | 70 (9.0) | |
| Socioeconomic status | 0.12 | ||||||
| Lowest | 47 (30.5) | 23 (31.1) | 24 (31.6) | 377 (25.3) | 196 (26.5) | 181 (23.9) | |
| Middle | 48 (32.0) | 25 (33.8) | 23 (30.3) | 420 (28.1) | 217 (29.4) | 203 (26.8) | |
| Highest | 55 (36.7) | 26 (35.1) | 29 (38.7) | 700 (46.9) | 326 (44.1) | 374 (49.3) | |
| Missing | 4 (2.6) | 2 (2.6) | 2 (2.6) | 43 (2.8) | 21 (2.8) | 22 (2.8) | |
| Comorbidities | |||||||
| Diabetes | 16 (10.39) | 10 (13.16) | 6 (7.69) | 39 (2.53) | 28 (3.68) | 11 (1.41) | <0.01 |
| Hypertension | 29 (18.83) | 19 (25) | 10 (12.82) | 128 (8.31) | 58 (7.63) | 70 (8.97) | <0.01 |
| Dyslipidemia | 19 (12.34) | 11 (14.47) | 8 (10.26) | 115 (7.47) | 45 (5.92) | 70 (8.97) | 0.03 |
| Concurrent medications | |||||||
| Calcium supplementation | 83 (53.90) | 44 (57.89) | 39 (50.00) | 145 (9.42) | 35 (4.61) | 110 (14.10) | <0.01 |
| Vitamin D (cholecalciferol, ergocalciferol) | 55 (35.71) | 23 (30.26) | 32 (41.03) | 127 (8.25) | 27 (3.55) | 100 (12.82) | <0.01 |
| Active vitamin D (calcitriol, alfacalcidol) | 151 (98.1) | 74 (97.4) | 77 (98.7) | 13 (0.8) | 4 (0.5) | 9 (1.2) | <0.01 |
Data are shown as the mean ± SD or n (%).
SD, standard deviation.
*P-value for total case group vs. matched control group.